Pfizer Ventures
Pfizer Ventures is the strategic corporate venture capital arm of Pfizer Inc., founded in 2004. It invests globally in innovative biopharmaceutical companies advancing breakthrough medicines, platform technologies, and other healthcare technologies of current or future strategic interest to Pfizer.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 300% year-over-year (16 deals in the last 12 months). Average disclosed round size is $67.7M (across 168 rounds with reported amounts).
Portfolio
119
Fund Size
—
Top Stage
Series B
Last 12 Mo
16
Team
Michael C. Diem, MD
Vice President, WWBD / Senior Managing Partner
Anthony Barry, PhD
Executive Director, WWBD / Partner
Christopher O’Donnell, PhD
Vice President, WWBD / Partner
Irena Melnikova, PhD
Executive Director, WWBD / Partner
Jiaping Gu, PhD
Vice President, WWBD / Partner
Marie-Claire Peakman, MRCPharm, PhD
Executive Director, WWBD / Partner
Rana Al-Hallaq, PhD
Vice President, WWBD / Partner
Ama Amoah
Finance Director, Business Development
Alexandre de Germay
Chief International Commercial Officer, Executive Vice President
Andrew J. Muratore
Vice President & Chief Counsel, M&A and Licensing
Barbara Dalton
Pfizer Ventures
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 NextCure | Series B | $500M | Aug 2026 |
 Flare Therapeutics | Series C | — | Jun 2026 |
 Oblenio Bio | Series B | $62M | Jun 2026 |
| CCour Pharma | Series B | $50M | Jun 2026 |
 CellCentric | Series D | $220M | May 2026 |
 Storm Therapeutics | Series C | $56M | Apr 2026 |
| CCrossbow | Series B | — | Mar 2026 |
| TTRexBio, Inc. | Series C | $50M | Jan 2026 |
 Vibrant Therapeutics | Series C | $61M | Jan 2026 |
 Mediar | Series B | $76M | Jan 2026 |
 Trex Bio | Unknown | $50M | Jan 2026 |
| CCour Pharma | Series B | $50M | Jan 2026 |
| CCrossbow | Series B | $77M | Jan 2026 |
 FoRx Therapeutics | Series A | $50M | Dec 2025 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Artios | Series D | $115M | Nov 2025 |
 Mission Therapeutics | Unknown | $13.3M | Oct 2025 |
 Cartography Biosciences | Series B | — | Oct 2025 |
 Cartography | Series B | $67M | Oct 2025 |
 OTR Therapeutics | Series A | $100M | Jun 2025 |
 TRIMTECH Therapeutics | Seed | $14M | Mar 2025 |
 MindImmune Therapeutics, Inc. | Series A | $30M | Jan 2025 |
| CellCentric | Series C | $120M | Jan 2025 |
| OTR Therapeutics | Series A | $100M | Jan 2025 |
 Promise Bio | Seed | $8.3M | Dec 2024 |
Top Co-Investors
Last updated: 20 October 2026